Generic Apadaz Availability
Last updated on Jun 11, 2025.
Apadaz is a brand name of acetaminophen/benzhydrocodone, approved by the FDA in the following formulation(s):
APADAZ (acetaminophen; benzhydrocodone hydrochloride - tablet;oral)
-
Manufacturer: ZEVRA THERAP
Approval date: February 23, 2018
Strength(s): 325MG;EQ 6.12MG BASE (discontinued) [RLD] -
Manufacturer: ZEVRA THERAP
Approval date: January 4, 2019
Strength(s): 325MG;EQ 4.08MG BASE (discontinued) [RLD], 325MG;EQ 8.16MG BASE (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Apadaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Patent 8,461,137
Issued: June 11, 2013
Inventor(s): Mickle Travis & Guenther Sven & Mickle Christal & Chi Guochen & Kanski Jaroslaw & Martin Andrea K. & Bera Bindu
Assignee(s): KemPharm, Inc.The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Patent expiration dates:
- February 22, 2031✓✓
- February 22, 2031
-
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Patent 8,748,413
Issued: June 10, 2014
Inventor(s): Mickle Travis & Guenther Sven & Mickle Christal & Chi Guochen & Kanski Jaroslaw & Martin Andrea K. & Bera Bindu
Assignee(s): KemPharm, Inc.The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Patent expiration dates:
- July 1, 2030✓✓
- July 1, 2030
-
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Patent 8,828,978
Issued: September 9, 2014
Inventor(s): Mickle Travis & Guenther Sven & Mickle Christal & Chi Guochen & Kanski Jaroslaw & Martin Andrea K. & Bera Bindu
Assignee(s): KemPharm, Inc.The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Patent expiration dates:
- July 1, 2030✓
- July 1, 2030
-
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Patent 9,132,125
Issued: September 15, 2015
Inventor(s): Mickle Travis & Guenther Sven & Mickle Christal & Chi Guochen & Kanski Jaroslaw & Martin Andrea K. & Bera Bindu
Assignee(s): KemPharm, Inc.The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Patent expiration dates:
- July 1, 2030✓✓✓
- July 1, 2030
-
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Patent 9,549,923
Issued: January 24, 2017
Inventor(s): Mickle Travis & Guenther Sven & Mickle Christal & Chi Guochen & Kanski Jaroslaw & Martin Andrea K. & Bera Bindu
Assignee(s): KemPharm, Inc.The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Patent expiration dates:
- July 1, 2030✓✓
- July 1, 2030
More about Apadaz (acetaminophen / benzhydrocodone)
- Apadaz consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: narcotic analgesic combinations
- En español
Related treatment guides
Related/similar drugs
Paracetamol
Paracetamol (Panadol, Calpol, Alvedon) is a widely used over-the-counter painkiller and fever ...
Tylenol
Tylenol is a pain reliever and a fever reducer used to treat many conditions such as headaches ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Oxycodone
Oxycodone is an opioid analgesic used to treat moderate to severe pain; it has a high potential for ...
Naproxen
Naproxen is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by ...
Hydroxyzine
Hydroxyzine is an antihistamine used to treat itching, hives, and anxiety. It also acts as a ...
Tramadol
Tramadol is an opioid medication that may be used to treat moderate to moderately severe chronic ...
Cyclobenzaprine
Cyclobenzaprine is a muscle relaxant and works by blocking pain sensations. Includes ...
Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
